Navigation Links
US WorldMeds Acquires Solstice Neurosciences

LOUISVILLE, Ky., Aug. 13 /PRNewswire/ -- US WorldMeds, LLC, a Kentucky-based specialty pharmaceutical company that develops unique products to address unmet medical needs, today announced it has acquired Solstice Neurosciences, Inc. for $35 million.  The acquisition expands US WorldMeds' operations, adds to the company's growing portfolio of products and enhances the company's ability to create and deliver high-quality specialty pharmaceutical products to its targeted global markets.  

"By acquiring Solstice Neurosciences, US WorldMeds is bringing together the knowledge, passion and innovative spirit of two leading-edge companies," said P. Breckinridge "Breck" Jones, CEO of US WorldMeds.  "US WorldMeds is dedicated to leveraging our scientific expertise to develop novel specialty pharmaceuticals that make a difference in patients' lives.  I am confident this merger will lead to powerful new innovations and accelerate growth opportunities for our combined company."    

Solstice Neurosciences is a specialty biopharmaceutical company headquartered in Malvern, PA with a production and manufacturing facility in San Francisco.  The combined company, which will operate as US WorldMeds, will be headquartered in Louisville with Jones as CEO.  In conjunction with the Solstice merger, US WorldMeds announced the promotions of H. Lee Warren to Chief Operating Officer and Robert (Bob) Melhorn to Vice President Operations.  In addition, US WorldMeds expects to add up to 30 new employees by the end of 2010, including sales staff across the U.S. and corporate staff in Louisville.

The acquisition immediately expands US WorldMeds' product portfolio with the addition of Solstice's premier product, which is sold as MYOBLOC® (rimabotulinumtoxinB) Injection Solution in the U.S. and NeuroBloc® (Botulinum Toxin Type B) Injectable Solution in select overseas markets. Myobloc is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.  MYOBLOC remains the only type B botulinum toxin approved for use in the world.

Other products in US WorldMeds' product portfolio include Revonto™, a fast-reconstituting form of Dantrolene Sodium for Injection for the treatment of malignant hyperthermia, and Lofexidine, a non-narcotic treatment in late-stage development for acute opiate withdrawal symptoms.

MTS Securities, LLC, an affiliate of MTS Health Partners, L.P., served as the advisor to Solstice Neurosciences in the acquisition transaction.

About US WorldMeds

US WorldMeds is a Kentucky-based specialty pharmaceutical company that develops, licenses and commercializes unique medical therapies that address unmet patient needs.  US WorldMeds' products include novel treatments for malignant hyperthermia, cervical dystonia and symptoms of opiate withdrawal.  For more information, please visit


Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy. There have been reports of thrombophlebitis following administration of intravenous dantrolene. There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium.

Please see the full Prescribing Information for Revonto by visiting


MYOBLOC has a boxed warning related to the distant spread of toxin effect: The effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (eg, amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (eg, motor neuropathy) or neuromuscular junctional disorders (eg, myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (eg, curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Please see the full Prescribing Information and the Medication Guide for MYOBLOC by visiting Solstice Neurosciences' website at

Revonto is a trademark of US WorldMeds

MYOBLOC is a registered trademark of Solstice Neurosciences, Inc.

NeuroBloc is a registered trademark of Solstice Neurosciences, Inc.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. U.S. Preventive Medicine Acquires Specialty Disease Management
5. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
6. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
7. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
8. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
9. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
10. Wound Management Technologies Acquires Resorbable Orthopedics
11. Bausch & Lomb Acquires the Commercial Assets of Italian Ophthalmic Pharmaceuticals Company Tubilux
Post Your Comments:
(Date:11/26/2015)... Carolina , 26 november 2015 /PRNewswire/ ... (AAIPharma/CML) kondigt de geplande investering aan van ... van de laboratoria en het mondiale hoofdkantoor ... De uitbreiding zal resulteren in extra kantoorruimte ... voldaan aan de groeiende behoeften van de ...
(Date:11/26/2015)... , November 26, 2015 --> ... to use SyMRI to find optimal contrast weighting of MRI ... metastases, and has signed a research agreement with SyntheticMR in ... hospital. Using SyMRI, it is possible to generate multiple contrast ... after the patient has left, thus making it possible to ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
Breaking Medicine Technology:
(Date:11/27/2015)... , ... November 27, 2015 , ... ... November 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South ... 750,000. The digital component is distributed nationally, through a vast social media strategy ...
(Date:11/27/2015)... ... ... No.1 Herpes-only dating community in the world, revealed that over 50% of its members are ... people under the age of 50 – or 67% of the population - are infected ... HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder of ...
(Date:11/27/2015)... ... 27, 2015 , ... Intellitec Solutions announced today that they ... Recognized as Microsoft’s official group for end users of Dynamics SL ERP software, ... industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment to ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... ... November 27, 2015 , ... CBD College is ... Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. CBD College ... as only one of twelve colleges and universities in the state of California make ...
Breaking Medicine News(10 mins):